Neurocrine Biosciences

Neurocrine Biosciences, Inc. (NBIX) Investigated for Grossly Overcompensating Its Directors

Shareholder rights law firm Robbins LLP is investigating Neurocrine Biosciences (NASDAQ: NBIX) for gross overcompensation of its directors. After conducting an analysis of the director compensation of Neurocrine Therapeutics and its peer groups, we determined that Neurocrine Biosciences’ average director compensation differed from its peer groups’ by $263,605.50 for fiscal year 2018, $46,559.67 for fiscal year 2017, and $163,070.84 for fiscal year 2016.

If you are a former employee of Neurocrine Biosciences, Inc. (NBIX) and own stock, please contact us for more information about your rights and potential remedies.

Send us a message for more information.

Skip to content